Abstract: FR-PO1031
Detection of Cellular Respiration Pattern of Platelets and Peripheral Blood Mononuclear Cells in CKD
Session Information
- CKD Mechanisms: From Mendel to Mars
November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2303 CKD (Non-Dialysis): Mechanisms
Author
- Rewane, Ayesan, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Background
Reduced cellular respiration of platelets and increased respiration of peripheral blood mononuclear cells (PBMCs) were reported to be associated with more severe chronic heart diseases. This cellular phenotype remains to be established for patients with chronic kidney disease (CKD).
Methods
The analysis included stage 4 or 5 CKD patients and healthy controls with normal kidney function. The investigation was performed using Oroboros O2K-respirometer on intact and digitonin permeabilized cells. Cellular respiration was measured with a high resolution respirometry. Demographic and medical characteristics of participants including the cellular respiration of platelets and PBMCs were compared using Wilcoxon Rank Sum or Chi-square test.
Results
There were 27 CKD participants and 15 controls; median age (y) was 61 and 56, respectively. Two-third CKD subjects were African Americans and half of them were diabetic. The median GFR was 18 in the CKD group and 90 in the control group. There were no differences in white blood cell count or platelet count between the two groups. There was reduced respiration in the intact CKD platelets and in the permeabilized CKD platelets via Complex I & II of the electron transport chain (ETC). There was increased respiration in the intact CKD PBMCs as well as in the permeabilized CKD PBMCs via complex I & II of ETC.
Conclusion
Cellular respiration is reduced in CKD platelets and is increased in CKD PBMCs. Future studies should explore whether these cellular phenotypes result in a pro-inflammatory CKD state that is associated with worse cardiorenal outcomes.
Funding
- Private Foundation Support